Elanco Animal Health Incorporated (ELAN)
| Market Cap | 11.06B +155.8% |
| Revenue (ttm) | 4.72B +6.2% |
| Net Income | -232.00M |
| EPS | -0.47 |
| Shares Out | 499.38M |
| PE Ratio | n/a |
| Forward PE | 21.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,236,432 |
| Open | 22.33 |
| Previous Close | 22.09 |
| Day's Range | 22.10 - 22.75 |
| 52-Week Range | 9.32 - 27.72 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 27.89 (+25.91%) |
| Earnings Date | May 6, 2026 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ELAN stock is "Strong Buy." The 12-month stock price target is $27.89, which is an increase of 25.91% from the latest price.
News
Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock
Action Prepares Veterinarians and Livestock Producers with Prevention and Treatment Options Prior to Fly Being Detected in the U.S. Federal agencies grant emergency authorizations for New World screww...
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a...
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*
Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dog Adjustable collar fits comfortably and securely on a dog of any size Strengthens Ela...
Elanco Animal Health Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Innovation-driven growth exceeded expectations in 2025, with key products like Quattro and Zenrelia expanding market share and driving higher guidance for 2026. International expansion, robust R&D pipeline, and operational efficiencies—including AI adoption—support a positive multi-year outlook.
Elanco Animal Health Transcript: Leerink Global Healthcare Conference 2026
Strong Q4 results and raised 2026 innovation revenue targets reflect momentum across pet and farm segments. Operational efficiencies, robust product launches, and a disciplined capital strategy support margin expansion and future growth. Farm business and innovation pipeline are key drivers.
Elanco Animal Health Transcript: Barclays 28th Annual Global Healthcare Conference
Strong Q4 2025 results and robust innovation drove growth across all business segments, with key products like Quattro and Zenrelia expanding market share. 2026 guidance projects continued revenue, margin, and EPS growth, supported by operational efficiencies and a rich pipeline of future launches.
Elanco Animal Health Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 2025 results and robust 2026 guidance reflect momentum from innovation-led growth, with Quattro and Zenrelia driving performance. Strategic focus includes margin expansion, AI-driven efficiencies, and continued deleveraging, positioning the company for long-term growth and additional blockbuster launches.
Elanco Animal Health Transcript: BofA Securities Animal Health Summit
Management highlighted strong financial performance, raised innovation revenue targets, and detailed robust momentum for key products like Zenrelia, Befreba, and Quattro. Competitive pressures and pricing strategies are addressed, with operational initiatives set to drive margin expansion and long-term growth.
Elanco Animal Health Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year 2025 results, with 9% organic revenue growth and outperformance in innovation. 2026 guidance calls for 4%-6% revenue growth, margin expansion, and continued investment in launches and R&D, supported by robust pet and farm animal demand.
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day Outlook Fourth Quarter 2025 Financial ...
Elanco to Participate in Upcoming Investor Conferences
INDIANAPOLIS, Ind., Feb. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
Elanco Announces Updates to Board of Directors
INDIANAPOLIS, Feb. 13, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re...
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco w...
Elanco Animal Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong innovation and product launches are driving mid-single-digit growth, with six blockbusters and a robust $2 billion pipeline. Operational efficiency, value-based pricing, and global expansion support high single-digit EBITDA and low double-digit EPS growth, with leverage targeted below 3x by 2027.
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age...
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional A...
Jim Cramer Praises Elanco Animal Health: 'They've Turned That Company Around'
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Elanco Animal Health Incorporated (NYSE: ELAN).
Animal Health Focused Elanco Details Pipeline Momentum, US Investments, Cost-Saving Plans
On Tuesday, Elanco Animal Health Incorporated (NYSE: ELAN) used its first Investor Day in five years to signal a turning point for the company, outlining a more focused strategy aimed at sustainable g...
Elanco Animal Health Transcript: Investor Day 2025
Focused on sustainable, mid-single-digit revenue growth, the company is leveraging a robust innovation pipeline, operational efficiency, and disciplined capital allocation to drive high single-digit EBITDA growth and $1 billion in free cash flow over three years. Expansion in both pet and farm animal markets, global launches, and productivity initiatives underpin a durable, competitive position.
Elanco Investor Day Defines New Era as Sustainable Growth Company
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and lo...
Elanco Animal Health Transcript: Piper Sandler 37th Annual Healthcare Conference
Margin expansion is expected through innovation, cost initiatives, and operational efficiencies. Key products like Quattro, Zenrelia, and Experior are driving growth, with rapid international expansion and strong farm business margins. Deleveraging and disciplined capital allocation remain priorities.
Elanco Animal Health Transcript: Evercore ISI 8th Annual HealthCONx Conference
Growth, innovation, and cash remain top priorities, with nine quarters of growth and a robust innovation pipeline driving revenue and EBITDA improvements. Leverage reduction and productivity initiatives are underway, and further details on long-term strategy and 2026 outlook will be shared at the upcoming investor day.
Elanco executive appointed as Neurizon's Board Observer
MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advanc...
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.